Biweekly GLP-1 Injection Shows Promise for Blood Sugar Control and Weight Management
A new biweekly injection, bofanglutide, has shown significant potential in managing blood sugar levels and promoting weight loss among individuals with type 2 diabetes, according to findings from a phase 2b clinical trial. Unlike established GLP-1 medications such as Ozempic and Wegovy, which are administered once a week, this innovative treatment requires injections only every…
